Zobrazeno 1 - 10
of 30
pro vyhledávání: '"David H. Salinger"'
Autor:
Samira Merali, David H. Salinger, Maria Palmisano, Amy J. Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amit Roy, Vidya Perera
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 9, Pp 1448-1461 (2024)
Abstract Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The phase III EXPLORER‐HCM (NCT03470545) study use
Externí odkaz:
https://doaj.org/article/2d97afb3b2c44e46bccc7c6593bb0036
Autor:
Peter Chang, Vidya Perera, David H. Salinger, Samira Merali, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amy J. Sehnert, Maria Palmisano, Amit Roy
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 9, Pp 1462-1475 (2024)
Abstract Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PopPK) model was dev
Externí odkaz:
https://doaj.org/article/eaceb752f6ca46f980e5f1d94592e26c
Autor:
Vishak Subramoney, Jerry R Nedelman, David H Salinger, Mengchun Li, Mel Spigelman, Rob Woolson, Daniel Everitt, Mendel Carl M, Karen Wade
Publikováno v:
Antimicrobial Agents and Chemotherapy
Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intoleran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74dbafb8a3a94dab3539b14888a1535
https://doi.org/10.1128/aac.01121-20
https://doi.org/10.1128/aac.01121-20
Autor:
Mengchun Li, Daniel Everitt, Jerry R Nedelman, Mendel Carl M, David H Salinger, Angelo del Parigi, Hanbin Li
Publikováno v:
Antimicrobial Agents and Chemotherapy
Concentration-QTc modeling was applied to pretomanid, a new nitroimidazooxazine antituberculosis drug. Data came from eight phase 2 and phase 3 studies.
Concentration-QTc modeling was applied to pretomanid, a new nitroimidazooxazine antitubercul
Concentration-QTc modeling was applied to pretomanid, a new nitroimidazooxazine antitubercul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb3c9495ba77c9cb4b47749d6b6baaf
https://doi.org/10.1128/aac.00445-19
https://doi.org/10.1128/aac.00445-19
Publikováno v:
Antimicrobial Agents and Chemotherapy
A population pharmacokinetic (PopPK) model for pretomanid was developed using data from 14 studies in the pretomanid development program: six phase 1 studies, six phase 2 studies, and two phase 3 studies. The final analysis data set contained 17,725
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f37bca01ecce141a5a6181d3be00bc
https://pubmed.ncbi.nlm.nih.gov/31405856
https://pubmed.ncbi.nlm.nih.gov/31405856
Publikováno v:
Antimicrobial Agents and Chemotherapy
The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are giv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c60c0e021991cff7a23ef52d28801f
https://pubmed.ncbi.nlm.nih.gov/31451504
https://pubmed.ncbi.nlm.nih.gov/31451504
Autor:
David H. Salinger, Paul O'Donnell, Donald E. Mager, Brenda M. Sandmaier, Claudio Anasetti, Jeannine S. McCune, Paolo Vicini
Publikováno v:
Cancer Chemotherapy and Pharmacology. 75:67-75
Quantitative relationships between 9-β-d-arabinofuranosyl-2-fluoroadenine (F-ara-A) concentrations and lymphosuppression have not been reported, but would be useful for regimen design. A population pharmacokinetic/pharmacodynamic model was construct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99d20dbf968dd1d47d5a1d5364158991
https://doi.org/10.1007/s00280-014-2618-2
https://doi.org/10.1007/s00280-014-2618-2
Autor:
Ajay Nirula, Megan A. Gibbs, Marc R. Gastonguay, David Martin, Kathleen Köck, David H. Salinger, Paul Klekotka, Endres Christopher J
Publikováno v:
The Journal of Clinical Pharmacology. 54:1230-1238
Brodalumab, a human monoclonal IgG2-antibody, acts as a potent antagonist at the interleukin-17 receptor A, which is important in the pathogenesis of psoriasis. To characterize the pharmacokinetics of brodalumab and assess the effects of covariates,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::519294b171f08fcc425def8a6dfd74ea
https://doi.org/10.1002/jcph.334
https://doi.org/10.1002/jcph.334
Publikováno v:
Clinical Pharmacology in Drug Development. 3:276-283
Pharmacokinetic-pharmacodynamic (PK-PD) modeling can provide a framework for quantitative "learning and confirming" from studies in all phases of drug development. Brodalumab is a human monoclonal antibody (IgG2 ) targeting the IL-17 receptor A that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bf1d1e1aaa142368fab68a8346db2af
https://doi.org/10.1002/cpdd.103
https://doi.org/10.1002/cpdd.103
Autor:
Chris B. Russell, Gary J. Williams, Kim A. Papp, David H. Salinger, David Martin, Hua Dong, James G. Krueger, Peter Foley, C. Reid, Rod Sinclair
Publikováno v:
Journal of Investigative Dermatology. 132:2466-2469
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2b0996869ab625af26229e49770fb4
https://doi.org/10.1038/jid.2012.163
https://doi.org/10.1038/jid.2012.163